Implementing a bioavailability enhancing formulation approach can positively impact safety, efficacy, and patient adherence, leading to successful clinical outcomes. This article takes an in-depth look at how lipid-based drug delivery systems (LBDDS) can be used as a bioavailability enhancing technology, as well as the softgel dosage form for their delivery, in order to achieve successful clinical outcomes.
A London-based pharmaceutical company is developing treatments for unmet medical needs, including rare diseases, with the aim of improving the health and quality of life of patients worldwide. Learn how the company employed a structured three-step approach to help overcome the challenges of molecular characterization and a limited budget.
A biotechnology company had developed a new chemical entity for the treatment of a severe pediatric genetic disease. However, numerous drug delivery challenges threatened the realization of the Fast Track status designation they had received due to promising early-stage results. By leveraging a softgel technology the company was able to overcome a number of potential hurdles and expeditiously enter the Phase II/III clinical trial.
Catalent Biologics is your one integrated partner with the expertise to get your biologic to market faster. We have the passion to help you accelerate, simplify, and de-risk your next biologic from development and manufacturing, to fill/finish, clinical supply, and commercial launch.